Candidemia in Immunocompromised Patients: Dental Diagnosis, Treatment, and Nursing Care-An Updated Review

Background: Candidemia is a major healthcare-associated bloodstream infection associated with substantial morbidity and mortality, particularly among critically ill and immunocompromised patients. Its management remains challenging because of diagnostic delays, increasing antifungal resistance, and differences in the epidemiology of Candida species across geographical regions. Aim: This review examines the epidemiology, antifungal susceptibility, diagnostic approaches, and current therapeutic strategies for candidemia, with emphasis on emerging resistance patterns and clinical management challenges. Methods: Relevant literature was reviewed to summarize the distribution of Candida species, regional antifungal resistance profiles, and advances in diagnostic methods. The review also evaluates conventional blood cultures, molecular techniques, next-generation sequencing, T2 Candida, MALDI-TOF, non-culture-based biomarkers, and biosensors. Therapeutic approaches, including antifungal prophylaxis, empirical and targeted treatment, vascular catheter removal, ophthalmological assessment, therapeutic monitoring, and emerging antifungal agents, were also examined. Results: Non-albicans Candida species are increasingly contributing to candidemia, with substantial geographical variation in antifungal susceptibility. Although blood cultures remain the diagnostic reference standard, their limited sensitivity and delayed results support the use of rapid molecular and biomarker-based techniques. Echinocandins remain the preferred initial treatment for many non-neutropenic patients with candidemia. However, treatment outcomes are influenced by species identification, antifungal susceptibility, infection site, pharmacokinetic and pharmacodynamic factors, and timely source control. New agents, including rezafungin and fosmanogepix, offer potential therapeutic alternatives. Conclusion: Improved outcomes require early diagnosis, appropriate antifungal selection, source control, and individualized management guided by microbiological findings and patient characteristics.

Authors

Institutions

Publication Details

Journal
Saudi Journal of Medicine and Public Health
Published
2026-11-18
DOI
https://doi.org/10.64483/202631869
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Candidemia in Immunocompromised Patients: Dental Diagnosis, Treatment, and Nursing Care-An Updated Review

Hanan Abdulrahman Abdulah Ali, Amal Mohammed Ibn Mandeel, Waad Saad Aldossari, Shafega Ali Shajri et al.
Saudi Journal of Medicine and Public Health
Antifungal resistance and susceptibility
article

Candidemia in Immunocompromised Patients: Dental Diagnosis, Treatment, and Nursing Care-An Updated Review

Hanan Abdulrahman Abdulah Ali, Amal Mohammed Ibn Mandeel, Waad Saad Aldossari, Shafega Ali Shajri, Aisha Marie Alsayed, Athyaha Hanaif Okashan Alruwaili, Mashael Hussain Albalushei, Wushaylah Qasem Ali Ahmadi, Amal Saif Alsubaei, Aishah Hassan Ali Magrashi, Fatima Qasim Ali Ahmadi, Salmah Mansour Alazmi
article en

Abstract

Background: Candidemia is a major healthcare-associated bloodstream infection associated with substantial morbidity and mortality, particularly among critically ill and immunocompromised patients. Its management remains challenging because of diagnostic delays, increasing antifungal resistance, and differences in the epidemiology of Candida species across geographical regions. Aim: This review examines the epidemiology, antifungal susceptibility, diagnostic approaches, and current therapeutic strategies for candidemia, with emphasis on emerging resistance patterns and clinical management challenges. Methods: Relevant literature was reviewed to summarize the distribution of Candida species, regional antifungal resistance profiles, and advances in diagnostic methods. The review also evaluates conventional blood cultures, molecular techniques, next-generation sequencing, T2 Candida, MALDI-TOF, non-culture-based biomarkers, and biosensors. Therapeutic approaches, including antifungal prophylaxis, empirical and targeted treatment, vascular catheter removal, ophthalmological assessment, therapeutic monitoring, and emerging antifungal agents, were also examined. Results: Non-albicans Candida species are increasingly contributing to candidemia, with substantial geographical variation in antifungal susceptibility. Although blood cultures remain the diagnostic reference standard, their limited sensitivity and delayed results support the use of rapid molecular and biomarker-based techniques. Echinocandins remain the preferred initial treatment for many non-neutropenic patients with candidemia. However, treatment outcomes are influenced by species identification, antifungal susceptibility, infection site, pharmacokinetic and pharmacodynamic factors, and timely source control. New agents, including rezafungin and fosmanogepix, offer potential therapeutic alternatives. Conclusion: Improved outcomes require early diagnosis, appropriate antifungal selection, source control, and individualized management guided by microbiological findings and patient characteristics.

Saudi Journal of Medicine and Public HealthVol. 3(1)
Ministry of Health (SA), Ministry of Health (KW), East Jeddah Hospital (SA)
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon